[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Friday Afternoon",
    "summary": "Health care stocks declined Friday afternoon, with the NYSE Health Care Index shedding 0.3% and the",
    "url": "https://finnhub.io/api/news?id=e256e293db81704788927e494d2c4fdec99dee69ec674f58aa69eb012702e697",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749837596,
      "headline": "Sector Update: Health Care Stocks Softer Friday Afternoon",
      "id": 135257559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks declined Friday afternoon, with the NYSE Health Care Index shedding 0.3% and the",
      "url": "https://finnhub.io/api/news?id=e256e293db81704788927e494d2c4fdec99dee69ec674f58aa69eb012702e697"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan biotech/pharma analysts hold analyst/industry conference call",
    "summary": "US SMid Biotech Analyst Rama and US Major & Specialty Pharmaceuticals Analyst Schott, along with Dr. Charles Ryan, Genitourinary Medical Oncologist at Memorial Sloan Kettering Cancer Center discuss the evolving treatment landscape in prostate cancer (relevant companies PFE ORIC JNJ) on an Analyst/Industry conference call to be held on June 12 at 2 pm. Webcast Link Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Sto",
    "url": "https://finnhub.io/api/news?id=123b38920801599ad83f4172beb0578ba7dbc2df2d6aa746ffce0e30b7221158",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749828608,
      "headline": "JPMorgan biotech/pharma analysts hold analyst/industry conference call",
      "id": 135251052,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "US SMid Biotech Analyst Rama and US Major & Specialty Pharmaceuticals Analyst Schott, along with Dr. Charles Ryan, Genitourinary Medical Oncologist at Memorial Sloan Kettering Cancer Center discuss the evolving treatment landscape in prostate cancer (relevant companies PFE ORIC JNJ) on an Analyst/Industry conference call to be held on June 12 at 2 pm. Webcast Link Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Sto",
      "url": "https://finnhub.io/api/news?id=123b38920801599ad83f4172beb0578ba7dbc2df2d6aa746ffce0e30b7221158"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not been previously treated with CAR T-cell therapy.1 Findings demonstrate the potential of JNJ-4496 in the treatment of patients with R/R LBCL, including",
    "url": "https://finnhub.io/api/news?id=2a80c6d113a0857895d75b567650e767a76088204b03b359f5b570a9b23e835a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749826800,
      "headline": "Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma",
      "id": 135253073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not been previously treated with CAR T-cell therapy.1 Findings demonstrate the potential of JNJ-4496 in the treatment of patients with R/R LBCL, including",
      "url": "https://finnhub.io/api/news?id=2a80c6d113a0857895d75b567650e767a76088204b03b359f5b570a9b23e835a"
    }
  },
  {
    "ts": null,
    "headline": "BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?",
    "summary": "Boston Scientific's Q1 2025 Endoscopy sales jump 6%, powered by innovation in stents, clips and surgical tools for GI care.",
    "url": "https://finnhub.io/api/news?id=6269e3aa27a0eb93de3dbd223956a1d3550196fc36c7b569d3fcd51072cdeeb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749817140,
      "headline": "BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?",
      "id": 135248564,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Boston Scientific's Q1 2025 Endoscopy sales jump 6%, powered by innovation in stents, clips and surgical tools for GI care.",
      "url": "https://finnhub.io/api/news?id=6269e3aa27a0eb93de3dbd223956a1d3550196fc36c7b569d3fcd51072cdeeb5"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson T-Cell Therapy Shows Promising Initial Results in Lymphoma Study",
    "summary": "By Kelly Cloonan Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating...",
    "url": "https://finnhub.io/api/news?id=7e5504568f4f9fd2156e3ba3950bc6f526e40b825f9f6b4cb92d1e06b24d9d19",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749815955,
      "headline": "Johnson & Johnson T-Cell Therapy Shows Promising Initial Results in Lymphoma Study",
      "id": 135253320,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "By Kelly Cloonan Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating...",
      "url": "https://finnhub.io/api/news?id=7e5504568f4f9fd2156e3ba3950bc6f526e40b825f9f6b4cb92d1e06b24d9d19"
    }
  },
  {
    "ts": null,
    "headline": "Impax Ellevate Global Women's Leadership Fund Q1 2025 Commentary",
    "summary": "During the first quarter, the Global Womenâs Leadership portfolio lagged global developed market equities overall in the period.",
    "url": "https://finnhub.io/api/news?id=316577c6f240ae7b7ec97c54bca8c839df1a84fa3376c8a75b1ce5259d9bf6e2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749791940,
      "headline": "Impax Ellevate Global Women's Leadership Fund Q1 2025 Commentary",
      "id": 135235419,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1342783234/image_1342783234.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "During the first quarter, the Global Womenâs Leadership portfolio lagged global developed market equities overall in the period.",
      "url": "https://finnhub.io/api/news?id=316577c6f240ae7b7ec97c54bca8c839df1a84fa3376c8a75b1ce5259d9bf6e2"
    }
  }
]